---
title: 'Oncogenic and immunological targets for matched therapy of pediatric blood
  cancer patients: Dutch iTHER study experience'
date: '2024-07-16'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39011126/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240716183906&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Over the past 10 years, institutional and national molecular tumor boards
  have been implemented for relapsed or refractory pediatric cancer to prioritize
  targeted drugs for individualized treatment based on actionable oncogenic lesions,
  including the Dutch iTHER platform. Hematological malignancies form a minority in
  precision medicine studies. Here, we report on 56 iTHER leukemia/lymphoma patients
  for which we considered cell surface markers and oncogenic aberrations as actionable
  ...
disable_comments: true
---
Over the past 10 years, institutional and national molecular tumor boards have been implemented for relapsed or refractory pediatric cancer to prioritize targeted drugs for individualized treatment based on actionable oncogenic lesions, including the Dutch iTHER platform. Hematological malignancies form a minority in precision medicine studies. Here, we report on 56 iTHER leukemia/lymphoma patients for which we considered cell surface markers and oncogenic aberrations as actionable ...